Internal Hernias After Laparoscopic Gastric Bypass (IHafterLRYGB)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The main goal of this study is to describe the trends in the incidence rate of internal hernia presentation after different modifications of the mesenteric closure technique after primary laparoscopic Roux-en-Y gastric bypass (RYGB) surgery from 1997-2009.
Closure technique for mesocolic defect: 1- non-closure, 2- running with absorbable material, 3- interrupted with non-absorbable material, and 4- running with non-absorbable [ Time Frame: throughout follow-up ]
recurrence of symptomatic mesocolic internal hernia [ Time Frame: throughout follow-up ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients presenting with internal hernia after different modifications of the mesenteric closure technique after Primary Laparoscopic RYGB surgery from 1997-2009.
patient status post primary laparoscopic standard RYGB surgery who underwent internal hernia reduction and repair with any or the combination of the following:
closure of synchronous mesocolic or mesenteric space defects without incarcerated bowel
conversion to open (laparotomy)
small bowel resection with or without reversal
status post primary laparoscopic standard RYGB surgery with incidental finding of internal hernia space defect with or without bowel through the defect
any other type of re-operative surgery after primary standard RYGB
patient age < 18 years
missing records and/or unreachable patients with scant information for analysis